A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.
第一作者:
Frederik,Nevens
第一单位:
Department of Gastroenterology and Hepatology, University Hospitals, KU Leuven, Belgium.
作者:
关键词
ACLF, acute-on-chronic liver failureAD, acute decompensation of liver cirrhosisAE, adverse eventAESI, AE of special interestATMP, advanced therapy medicinal productAlcoholic liver diseaseBW, body weightCRP, C-reactive proteinEASL-CLIF, European Association for the Study of Chronic Liver FailureHALPC, human allogeneic liver-derived progenitor cellsINR, international normalised ratioLiver regenerative medicineMELD, model for end-stage liver diseaseMSC, mesenchymal stem cellsSAE, serious AESAS, safety analysis setSUSAR, suspected unexpected serious adverse reactionStem cellTEG, thromboelastographyTGT, thrombin generation testi.v., intravenous
DOI
10.1016/j.jhepr.2021.100291
PMID
34169246
发布时间
2024-07-09
- 浏览1
JHEP reports
2021年3卷4期
100291页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



